PT - JOURNAL ARTICLE AU - Lee, Justin AU - Bates, Matthew AU - Shepherd, Ewen AU - Riley, Stephen AU - Henshaw, Michael AU - Metherall, Peter AU - Daniel, Jim AU - Blower, Alison AU - Scoones, David AU - Wilkinson, Michele AU - Richmond, Neil AU - Robinson, Clifford AU - Cuculich, Phillip AU - Hugo, Geoffrey AU - Seller, Neil AU - McStay, Ruth AU - Child, Nicholas AU - Thornley, Andrew AU - Kelland, Nicholas AU - Atherton, Philip AU - Peedell, Clive AU - Hatton, Matthew TI - Cardiac stereotactic ablative radiotherapy for control of refractory ventricular tachycardia: initial UK multicentre experience AID - 10.1136/openhrt-2021-001770 DP - 2021 Nov 01 TA - Open Heart PG - e001770 VI - 8 IP - 2 4099 - http://openheart.bmj.com/content/8/2/e001770.short 4100 - http://openheart.bmj.com/content/8/2/e001770.full SO - Open Heart2021 Nov 01; 8 AB - Background Options for patients with ventricular tachycardia (VT) refractory to antiarrhythmic drugs and/or catheter ablation remain limited. Stereotactic radiotherapy has been described as a novel treatment option.Methods Seven patients with recurrent refractory VT, deemed high risk for either first time or redo invasive catheter ablation, were treated across three UK centres with non-invasive cardiac stereotactic ablative radiotherapy (SABR). Prior catheter ablation data and non-invasive mapping were combined with cross-sectional imaging to generate radiotherapy plans with aim to deliver a single 25 Gy treatment. Shared planning and treatment guidelines and prospective peer review were used.Results Acute suppression of VT was seen in all seven patients. For five patients with at least 6 months follow-up, overall reduction in VT burden was 85%. No high-grade radiotherapy treatment-related side effects were documented. Three deaths (two early, one late) occurred due to heart failure.Conclusions Cardiac SABR showed reasonable VT suppression in a high-risk population where conventional treatment had failed.Data are available upon reasonable request.